Incyte expects its atopic dermatitis and vitiligo treatment Opzelura to be a “key contributor” to growth in 2024 after sales jumped 78% in the fourth quarter.
Opzelura brought in $109.2 million in the last three months of the year, with the increase driven largely by new patients, expanded payer coverage and prescription refills in both indications.
“We remain very optimistic about the long-term potential of Opzelura as we continue to see strong uptake,” Barry Flannelly, Incyte’s executive VP and general manager of North America, said during Tuesday’s earnings call, describing it as “one of the best recent dermatology launches.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.